BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-361@pharmaconomics
DTSTAMP:20260707T015433Z
DTSTART;VALUE=DATE:20260524
DTEND;VALUE=DATE:20260525
SUMMARY:BIIB PDUFA — LEQEMBI IQLIK
DESCRIPTION:The FDA's approval decision on LEQEMBI IQLIK for its lead indication is due May 24\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/exhibit991-q42025pressrele.htm\n\nTrack it: https://pharmaconomics.com/e/361
URL:https://pharmaconomics.com/e/361
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BIIB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR